Radiomic features predict local failure-free survival in stage III NSCLC adenocarcinoma treated with chemoradiation

José Marcio Luna; Andrew R. Barsky; Russell T. Shinohara; Alexandra D. Dreyfuss; Leonid Roshkovan; Michelle Hershman; Babak Haghighi; Bardia Yousefi; Peter B. Noel; Keith A. Cengel; Sharyn Katz; Eric S. Diffenderfer; Despina Kontos

doi:10.1117/12.2581873

15 February 2021 Radiomic features predict local failure-free survival in stage III NSCLC adenocarcinoma treated with chemoradiation

José Marcio Luna, Andrew R. Barsky, Russell T. Shinohara, Alexandra D. Dreyfuss, Leonid Roshkovan, Michelle Hershman, Babak Haghighi, Bardia Yousefi, Peter B. Noel, Keith A. Cengel, Sharyn Katz, Eric S. Diffenderfer, Despina Kontos

Author Affiliations +

Proceedings Volume 11597, Medical Imaging 2021: Computer-Aided Diagnosis; 1159720 (2021) https://doi.org/10.1117/12.2581873
Event: SPIE Medical Imaging, 2021, Online Only

Conference Poster

Abstract

Prognosis plays a crucial role in the customization of lung cancer care. The effective prediction of treatment response is essential to tailor treatment decisions to lung cancer patients. Molecular characterization of tumors using genomics-based approaches is important for personalized treatment planning, however, repeated tumor biopsies should be performed to capture their molecular heterogeneity, putting patients at risk of procedural complications such as a pneumothorax. Furthermore, the recent addition of immunotherapy after chemoradiotherapy for patients with unresectable stage III NSCLC can improve survival outcomes. The survival benefit achieved by stage III NSCLC patients undergoing chemoradiation is of interest since currently available biomarkers are inadequate to predict which patients are most likely to benefit from immunotherapy for first-line treatment along with chemoradiation. In this study, we investigate the association between local failure-free survival and radiomic features extracted from CT scans of stage III NSCLC adenocarcinoma patients. We retrospectively analyzed a well-curated cohort of 89 non-contrast enhanced CT scans from patients receiving homogeneous chemoradiation treatment. A set of 107 radiomic features was extracted using the pyradiomics package. In univariate analysis we performed log-rank tests per feature to predict risk of local failure. In multivariate analysis we applied principal component analysis to fit a Cox model to predict local failure-free survival. Univariate analysis showed that no individual radiomic feature can predict local failure-free survival, while multivariate analysis gave a C-index = 0.70, 95% CI = [0.56,0.85]. We conclude that radiomic features from CT scans, can predict local failure-free survival in stage III NSCLC.

Conference Presentation

Citation Download Citation

José Marcio Luna, Andrew R. Barsky, Russell T. Shinohara, Alexandra D. Dreyfuss, Leonid Roshkovan, Michelle Hershman, Babak Haghighi, Bardia Yousefi, Peter B. Noel, Keith A. Cengel, Sharyn Katz, Eric S. Diffenderfer, and Despina Kontos "Radiomic features predict local failure-free survival in stage III NSCLC adenocarcinoma treated with chemoradiation", Proc. SPIE 11597, Medical Imaging 2021: Computer-Aided Diagnosis, 1159720 (15 February 2021); https://doi.org/10.1117/12.2581873

ACCESS THE FULL ARTICLE

INSTITUTIONAL
Select your institution to access the SPIE Digital Library.

SELECT YOUR INSTITUTION

PERSONAL
Sign in with your SPIE account to access your personal subscriptions or to use specific features such as save to my library, sign up for alerts, save searches, etc.

PERSONAL SIGN IN

No SPIE Account? Create one

PURCHASE THIS CONTENT

SUBSCRIBE TO DIGITAL LIBRARY

50 downloads per 1-year subscription

Members: $195

Non-members: $335 ADD TO CART

25 downloads per 1 - year subscription

Members: $145

Non-members: $250 ADD TO CART

PURCHASE SINGLE ARTICLE

Includes PDF, HTML & Video, when available